Johnson & Johnson (JNJ) Operating Income (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Operating Income came in at $7.1 billion in Q2 2026, up 7.43% year-over-year from $6.6 billion in Q2 2025, and up 12.21% quarter-over-quarter from $6.4 billion in Q1 2026.
Analysis
Johnson & Johnson (JNJ) Operating Income (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Operating Income across 18 years of filings, most recently posting $7.1 billion for Q2 2026.
- In Q2 2026, Operating Income rose 7.43% year-over-year to $7.1 billion; the TTM figure through Jun 2026 stood at $26.0 billion (up 21.33% YoY), while the FY2025 annual figure was $25.4 billion, up 20.71% from the prior year.
- Operating Income came in at $7.1 billion for Q2 2026 at Johnson & Johnson, up from $6.4 billion in the prior quarter.
- In the past five years, Operating Income ranged from a high of $7.1 billion in Q2 2026 to a low of $3.6 billion in Q4 2024.
- Average Operating Income over 5 years is $5.7 billion, with a median of $5.8 billion recorded in 2023.
- Year-over-year, Operating Income plunged 38.1% in 2023 and jumped 53.01% in 2025.
- Over 5 years, Operating Income stood at $5.3 billion in 2022, then retreated by 19.78% to $4.3 billion in 2023, then slipped by 15.34% to $3.6 billion in 2024, then jumped by 53.01% to $5.5 billion in 2025, then climbed by 29.65% to $7.1 billion in 2026.
- Per Business Quant data, the three most recent Operating Income figures were $7.1 billion in Q2 2026, $6.4 billion in Q1 2026, and $5.5 billion in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 7.14 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 6.43 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | -584.00 Mn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | 4.75 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 4.27 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | 1.22 Bn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | -505.13 Mn |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 697.90 Mn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 330.80 Mn |
| 10 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 151.50 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 28, 2026 | 7.14 Bn |
| Mar 29, 2026 | 6.36 Bn |
| Dec 28, 2025 | 5.51 Bn |
| Sep 28, 2025 | 7.03 Bn |
| Jun 29, 2025 | 6.65 Bn |
| Mar 30, 2025 | 6.18 Bn |
| Dec 29, 2024 | 3.60 Bn |
| Sep 29, 2024 | 5.04 Bn |
| Jun 30, 2024 | 6.47 Bn |
| Mar 31, 2024 | 5.91 Bn |
| Dec 31, 2023 | 4.25 Bn |
| Oct 1, 2023 | 5.74 Bn |
| Jul 2, 2023 | 5.81 Bn |
| Apr 2, 2023 | 5.72 Bn |
| Jan 1, 2023 | 6.87 Bn |
| Oct 2, 2022 | 5.30 Bn |
| Jul 3, 2022 | 3.88 Bn |
| Apr 3, 2022 | 4.35 Bn |
| Oct 3, 2021 | 6.61 Bn |
| Jul 4, 2021 | 6.20 Bn |